Jeffrey Gross

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

A functional screening of the kinome identifies the Polo‐like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain

David R. Piper, S. Sredni, T. Tomita, 2017, Pediatric blood & cancer.